The episode details Apple's CEO transition from Tim Cook to John Ternus. The discussion, led by Mark Gurman, suggests Ternus will accelerate AI integration across Apple's ecosystem and focus on new product categories, potentially moving away from projects he reportedly disliked, such as the Vision Pro and the car project.
A White House executive order directing the FDA to expedite the review of psychedelic drugs is a major focus. This policy change is positioned as a significant catalyst for the biotech sector, dramatically shortening review times and de-risking the path to market for companies like Compass Pathways.
The CEO of Compass Pathways discusses the potential of synthetic psilocybin to treat severe, treatment-resistant depression. The conversation highlights promising clinical trial data showing rapid and durable effects, suggesting a paradigm shift away from daily medications toward intermittent, high-impact therapies.
The episode highlights how AI is becoming the central strategic focus for major technology companies. This is evident in Tesla's plan to boost capital spending to $25 billion for AI and robotics, and in the expectation that new Apple CEO John Ternus will embed AI more deeply into the company's products and operations.
Keep pulling the thread on Bloomberg Businessweek Weekend.